vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and DUCOMMUN INC (DCO). Click either name above to swap in a different company.

DUCOMMUN INC is the larger business by last-quarter revenue ($215.8M vs $121.8M, roughly 1.8× Core Laboratories Inc.). Core Laboratories Inc. runs the higher net margin — 4.2% vs 3.4%, a 0.8% gap on every dollar of revenue. On growth, DUCOMMUN INC posted the faster year-over-year revenue change (9.4% vs -1.4%). Core Laboratories Inc. produced more free cash flow last quarter ($517.0K vs $-78.8M). Over the past eight quarters, DUCOMMUN INC's revenue compounded faster (6.3% CAGR vs -3.4%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Ducommun Inc. is a global aerospace and defense manufacturing enterprise that provides complex structural components, electronic systems and professional engineering services. It mainly serves clients across the commercial aviation, military defense and space sectors, delivering high-reliability solutions for critical aerospace application scenarios.

CLB vs DCO — Head-to-Head

Bigger by revenue
DCO
DCO
1.8× larger
DCO
$215.8M
$121.8M
CLB
Growing faster (revenue YoY)
DCO
DCO
+10.8% gap
DCO
9.4%
-1.4%
CLB
Higher net margin
CLB
CLB
0.8% more per $
CLB
4.2%
3.4%
DCO
More free cash flow
CLB
CLB
$79.3M more FCF
CLB
$517.0K
$-78.8M
DCO
Faster 2-yr revenue CAGR
DCO
DCO
Annualised
DCO
6.3%
-3.4%
CLB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLB
CLB
DCO
DCO
Revenue
$121.8M
$215.8M
Net Profit
$5.1M
$7.4M
Gross Margin
27.7%
Operating Margin
1.5%
6.5%
Net Margin
4.2%
3.4%
Revenue YoY
-1.4%
9.4%
Net Profit YoY
9.9%
EPS (diluted)
$0.11
$0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
DCO
DCO
Q1 26
$121.8M
Q4 25
$138.3M
$215.8M
Q3 25
$134.5M
$212.6M
Q2 25
$130.2M
$202.3M
Q1 25
$123.6M
$194.1M
Q4 24
$129.2M
$197.3M
Q3 24
$134.4M
$201.4M
Q2 24
$130.6M
$197.0M
Net Profit
CLB
CLB
DCO
DCO
Q1 26
$5.1M
Q4 25
$4.9M
$7.4M
Q3 25
$14.2M
$-64.4M
Q2 25
$10.6M
$12.6M
Q1 25
$-154.0K
$10.5M
Q4 24
$7.4M
$6.8M
Q3 24
$11.7M
$10.1M
Q2 24
$9.0M
$7.7M
Gross Margin
CLB
CLB
DCO
DCO
Q1 26
Q4 25
20.8%
27.7%
Q3 25
22.0%
26.6%
Q2 25
20.3%
26.6%
Q1 25
19.5%
26.6%
Q4 24
17.8%
23.5%
Q3 24
20.5%
26.2%
Q2 24
21.2%
26.0%
Operating Margin
CLB
CLB
DCO
DCO
Q1 26
1.5%
Q4 25
11.5%
6.5%
Q3 25
15.6%
-37.7%
Q2 25
11.7%
8.5%
Q1 25
3.6%
8.5%
Q4 24
11.0%
5.3%
Q3 24
14.7%
7.6%
Q2 24
12.3%
7.1%
Net Margin
CLB
CLB
DCO
DCO
Q1 26
4.2%
Q4 25
3.6%
3.4%
Q3 25
10.6%
-30.3%
Q2 25
8.2%
6.2%
Q1 25
-0.1%
5.4%
Q4 24
5.7%
3.4%
Q3 24
8.7%
5.0%
Q2 24
6.9%
3.9%
EPS (diluted)
CLB
CLB
DCO
DCO
Q1 26
$0.11
Q4 25
$0.11
$0.52
Q3 25
$0.30
$-4.30
Q2 25
$0.22
$0.82
Q1 25
$0.00
$0.69
Q4 24
$0.15
$0.45
Q3 24
$0.25
$0.67
Q2 24
$0.19
$0.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
DCO
DCO
Cash + ST InvestmentsLiquidity on hand
$22.8M
$45.3M
Total DebtLower is stronger
$298.8M
Stockholders' EquityBook value
$275.1M
$662.1M
Total Assets
$587.7M
$1.2B
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
DCO
DCO
Q1 26
$22.8M
Q4 25
$22.7M
$45.3M
Q3 25
$25.6M
$50.9M
Q2 25
$31.2M
$37.1M
Q1 25
$22.1M
$30.7M
Q4 24
$19.2M
$37.1M
Q3 24
$21.5M
$37.3M
Q2 24
$17.7M
$29.4M
Total Debt
CLB
CLB
DCO
DCO
Q1 26
Q4 25
$110.3M
$298.8M
Q3 25
$114.1M
$215.0M
Q2 25
$124.6M
$218.1M
Q1 25
$124.4M
$229.9M
Q4 24
$126.1M
$229.8M
Q3 24
$139.9M
$246.0M
Q2 24
$147.6M
$250.9M
Stockholders' Equity
CLB
CLB
DCO
DCO
Q1 26
$275.1M
Q4 25
$266.0M
$662.1M
Q3 25
$271.3M
$649.0M
Q2 25
$261.3M
$707.8M
Q1 25
$253.4M
$693.0M
Q4 24
$246.6M
$682.5M
Q3 24
$250.7M
$665.6M
Q2 24
$240.3M
$655.9M
Total Assets
CLB
CLB
DCO
DCO
Q1 26
$587.7M
Q4 25
$584.0M
$1.2B
Q3 25
$591.4M
$1.2B
Q2 25
$602.1M
$1.1B
Q1 25
$591.5M
$1.1B
Q4 24
$585.1M
$1.1B
Q3 24
$600.5M
$1.1B
Q2 24
$597.8M
$1.1B
Debt / Equity
CLB
CLB
DCO
DCO
Q1 26
Q4 25
0.41×
0.45×
Q3 25
0.42×
0.33×
Q2 25
0.48×
0.31×
Q1 25
0.49×
0.33×
Q4 24
0.51×
0.34×
Q3 24
0.56×
0.37×
Q2 24
0.61×
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
DCO
DCO
Operating Cash FlowLast quarter
$4.0M
$-74.7M
Free Cash FlowOCF − Capex
$517.0K
$-78.8M
FCF MarginFCF / Revenue
0.4%
-36.5%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
0.77×
-10.03×
TTM Free Cash FlowTrailing 4 quarters
$22.5M
$-48.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
DCO
DCO
Q1 26
$4.0M
Q4 25
$7.9M
$-74.7M
Q3 25
$8.5M
$18.1M
Q2 25
$13.9M
$22.4M
Q1 25
$6.7M
$771.0K
Q4 24
$20.6M
$18.4M
Q3 24
$13.1M
$13.9M
Q2 24
$17.1M
$3.5M
Free Cash Flow
CLB
CLB
DCO
DCO
Q1 26
$517.0K
Q4 25
$5.0M
$-78.8M
Q3 25
$6.5M
$16.0M
Q2 25
$10.4M
$18.1M
Q1 25
$3.9M
$-4.0M
Q4 24
$17.4M
$14.6M
Q3 24
$10.4M
$12.0M
Q2 24
$14.3M
$144.0K
FCF Margin
CLB
CLB
DCO
DCO
Q1 26
0.4%
Q4 25
3.6%
-36.5%
Q3 25
4.8%
7.5%
Q2 25
8.0%
9.0%
Q1 25
3.1%
-2.1%
Q4 24
13.4%
7.4%
Q3 24
7.7%
5.9%
Q2 24
10.9%
0.1%
Capex Intensity
CLB
CLB
DCO
DCO
Q1 26
Q4 25
2.1%
1.9%
Q3 25
1.5%
1.0%
Q2 25
2.7%
2.1%
Q1 25
2.3%
2.5%
Q4 24
2.5%
2.0%
Q3 24
2.0%
1.0%
Q2 24
2.2%
1.7%
Cash Conversion
CLB
CLB
DCO
DCO
Q1 26
0.77×
Q4 25
1.61×
-10.03×
Q3 25
0.60×
Q2 25
1.31×
1.79×
Q1 25
0.07×
Q4 24
2.78×
2.72×
Q3 24
1.12×
1.37×
Q2 24
1.90×
0.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLB
CLB

Segment breakdown not available.

DCO
DCO

Other$90.1M42%
Militaryand Space$60.0M28%
Electronic Systems Segment$31.3M15%
Commercial Aerospace$24.8M11%
Estimate At Completion Adjustment$6.6M3%
Industrial$3.0M1%

Related Comparisons